Key Developments: Allergan plc (AGN)

AGN on New York Consolidated

2 Jul 2015
Change (% chg)

$0.60 (+0.20%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Actavis PLC announces pricing of public offerings of ordinary shares and mandatory convertible preferred shares
Wednesday, 25 Feb 2015 08:00am EST 

Actavis PLC:Has priced its concurrent offerings of 13,194,445 ordinary shares at $288.00 per share and 4,600,000 5.500 pct mandatory convertible preferred shares, Series A, at $1,000.00 per share, each being offered in a separate registered public offering.The net proceeds from the Ordinary Shares offering and the Mandatory Convertible Preferred Shares offering will be about $3.7 billion and $4.5 billion, respectively.J.P. Morgan, Mizuho Securities, Wells Fargo Securities, Morgan Stanley, Barclays and Citigroup are the joint book-running managers on the Ordinary Shares and Mandatory Convertible Preferred Shares offerings.  Full Article

Actavis PLC confirms generic uceris patent challenge
Tuesday, 24 Feb 2015 04:05pm EST 

Actavis PLC:Confirms that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Budesonide Extended-release Tablets, 9 mg.Actavis' ANDA product is a generic version of Salix Pharmaceuticals' Uceris, which is a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.  Full Article

Actavis PLC receives final approval for generic version of Subutex
Friday, 20 Feb 2015 08:45am EST 

Actavis PLC:Receives final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex (Buprenorphine 2 mg and 8 mg sublingual tablets).Actavis intends to begin shipping its product shortly.  Full Article

Actavis PLC proposes public offerings of ordinary shares
Thursday, 19 Feb 2015 07:38am EST 

Actavis PLC:Commences concurrent offerings totaling $8.4 bln, comprising $4.2 bln of ordinary shares and $4.2 bln of mandatory convertible preferred shares, Series A, each in a separate registered public offering, subject to market and other conditions.Intends to use the net proceeds, together with additional debt financing to finance the cash consideration for its previously announced acquisition of Allergan Inc and certain related transactions and financing expenses.J.P. Morgan, Mizuho Securities, Wells Fargo Securities, Morgan Stanley, Barclays and Citigroup are the joint book-running managers on the Ordinary Shares and Mandatory Convertible Preferred Stock offerings.  Full Article

Actavis plc gives FY 2015 outlook in line with analysts' estimates
Wednesday, 18 Feb 2015 06:30am EST 

Actavis plc:Expects FY 2015 total net revenue to be about $15 billion.FY 2015 non-GAAP earnings per diluted share to be between $16.30 and $17.30.FY 2015 revenue of $15.6 bln, EPS of $16.63 - Thomson Reuters I/B/E/S.  Full Article

Actavis PLC confirms temporary injunction from appeals Court related to Generic Pulmicort RESPULES
Tuesday, 17 Feb 2015 05:13pm EST 

Actavis PLC:Confirms that the United States Court of Appeals for the Federal Circuit has issued a temporary injunction to prevent Actavis.Prevent Actavis from further distribution of its generic version of Pulmicort RESPULES (budesonide inhalation suspension) 0.25, 0.5 mg pending its consideration of AstraZeneca's request for an injunction pending appeal.Actavis' sales of generic Pulmicort have been enjoined pending a hearing on the temporary injunction. A response for the hearing is due to the Court from Actavis by Feb. 20.Temporary injunction does not address product shipped prior to its issuance.Appeals Court ruling followed the Feb. 13 launch of Actavis' product after the United States District Court for the District of New Jersey found that (i) United States Patent No. 7,524,834 is invalid, and (ii) AstraZeneca's request for a permanent injunction is denied.Pulmicort RESPULESis a maintenance medicine used to control and prevent asthma symptoms in children ages 12 months to 8 years.  Full Article

Actavis to divest Pharmatech to TPG
Friday, 13 Feb 2015 08:30am EST 

Actavis PLC:Enters into definitive agreements, under which Actavis will divest to TPG the business currently known as Aptalis Pharmaceutical Technologies (Pharmatech) _ a pharmaceutical outsourcing and R&D business within Actavis' subsidiary Aptalis operating in the United States, Canada and Europe.No other Aptalis businesses or products are included in the transaction.No financial terms were disclosed.The transaction is expected to close by mid-2015, and is subject to customary closing conditions and regulatory approvals.  Full Article

Actavis PLC to Divest Doryx to Mayne Pharma
Monday, 9 Feb 2015 05:23pm EST 

Actavis PLC:Enters into an agreement with Mayne Pharma, under which it will divest the U.S. rights to the Doryx brand acne treatment and related assets to Mayne for about $50 mln.Transaction is expected to close prior to the end of Feb.Under the terms of the agreement, Actavis will continue to package, distribute and actively promote the product for a transition period until May 2 following the close of the transaction.  Full Article

AstraZeneca plc to acquire Actavis Plc's US respiratory portfolio
Thursday, 5 Feb 2015 02:02am EST 

Actavis plc and AstraZeneca plc:Says they have entered into a definitive agreement under which AstraZeneca will acquire the rights to Actavis' branded respiratory business in the U.S. and Canada.Initial consideration of $600 mln on completion and low single-digit royalties above a certain revenue threshold.Upon completion of the transaction, AstraZeneca will own the development and commercial rights in the U.S. and Canada to TudorzaPressair (aclidinium bromide inhalation powder).Anticipates the transaction will complete in the Q1 2015.  Full Article

Actavis PLC announces FDA acceptance of sNDA to expand TEFLARO
Wednesday, 4 Feb 2015 08:00am EST 

Actavis PLC:Says the US FDA has accepted for filing Actavis' supplemental New Drug Application (sNDA) to expand the label for TEFLARO(ceftaroline-fosamil) to treat cases of concurrent bacteremia in patients with acute bacterial skin and skin structure infections (ABSSSIs).Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target of Q3 2015 to complete its review.  Full Article

Eli Lilly wins UK Alimta drug patent case on appeal, shares jump

LONDON - Eli Lilly has won a patent case in the Court of Appeal in London over its blockbuster Alimta lung cancer drug, boosting prospects for future sales and dealing a blow to generic challenger Actavis, now renamed Allergan.

Search Stocks